Seite auswählen

In the US this year, the market environment for biotechnology stocks has experienced positive development in 2012. This resulted in price movements in stocks of biotechnology companies that have significantly outperformed the Dow Jones industrial average. Accordingly, M & A activity within this market has increased to a 4-year high. Currently, the M & A volume stands at about $25 billion, while in the same period of last year, this amounted to almost $10 billion.

The reasons for these developments are considered to be within the legal framework. Recent legislation has provided companies within the United States with a significant time advantage, as the time it takes a drug to brought into circulation was shortened. At the same time, patent difficulties including the expiration of many drug patents are placing pressure on inorganic growth.

[ilink url=““] Link zur Quelle ([/ilink]